advertisement

WGW-2021

11.13.4 Betablocker and prostaglandin (7)

Showing records 1 to 7

Display all abstracts in classification 11.13.4 Betablocker and prostaglandin

Search within classification 11.13.4 Betablocker and prostaglandin
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Tejwani S
Journal of cellular and molecular medicine 2020; 24: 5195-5204
86205 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
Oddone F; Tanga L
Advances in Therapy 2020; 37: 1436-1451
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Machiraju P; Nair AP
Journal of cellular and molecular medicine 2020; 24: 5195-5204
86205 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
Kóthy P; Holló G
Advances in Therapy 2020; 37: 1436-1451
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Ghosh A
Journal of cellular and molecular medicine 2020; 24: 5195-5204
86205 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

Advances in Therapy 2020; 37: 1436-1451
86654 Treatment of glaucoma by prostaglandin agonists and beta-blockers in combination directly reduces pro-fibrotic gene expression in trabecular meshwork
Das RK; Sethu S
Journal of cellular and molecular medicine 2020; 24: 5195-5204

Issue 21-2

Change Issue


advertisement

Oculus